THE CLOTHING SELECTION STUDY
Hello my name is Hyo Jung (Julie) Chang, and I am a Ph.D student in the Department of Consumer, Apparel and Retail Studies at the University of North Carolina, Greensboro.
First of all, thank you so much for showing your interest and reading this recruitment information.
I am working on my dissertation, which is to understand disabled consumers with regards to their clothing selection and how the clothing worn by disabled consumers are related to their self-concept and life satisfaction.
You can enter for a chance to win a $50 Visa gift card if you participate in the survey.
This is online survey, so you can go to the link and participate in the survey and it will take around 10 minutes.
The first page of the online survey is the consent form and you can mark the circle that you agree to participate in the survey. You can enter to win a $50 Visa gift card at the end of the survey.
Here is the anonymous survey link:
https://uncg.qualtrics.com/SE/?SID=SV_a96xYflhigZ6l48
If you have any questions, please contact to the researcher, h_chang@uncg.edu, or call me at
336-553-8692. If you know of anyone who may be interested in participating in the study, please forward the information to them. Your participation is truly appreciated. Thank you so much!
Sincerely,
Julie (Hyo Jung) Chang
----------
Hyo Jung (Julie) Chang
Doctoral Student/Graduate Assistant
Consumer, Apparel, & Retail Studies
210 Stone Building
University of North Carolina, Greensboro
Greensboro, NC 27402-6170
h_chang@uncg.edu
336-553-8692
Local Clinical Trial Recruiting Patients
The Multiple Sclerosis Center
Advance Neurology and Pain
152 E. Kinderton Way, Suite 101
Advance, NC 27006
336-940-2781
336-941-3100 (fax)
www.cornerstonehealthcare.com
A Multicenter, Double Blind, Parallel Group Placebo Controlled Study of the Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis who are treated with Interferon-beta. EFC6058: NCT01252355
Teriflunimide
Teriflunimide is an oral agent being developed for the treatment of relapsing-remitting MS. As a monotherapy it is effective in decreasing relapse rates, disability progression, and new MRI lesions. It’s effects were modest and it has a good safety profile. In combination with interferons in phase II trials it appears highly effective. The combination of interferon and teriflunimide could be as effective as Ocrelizumab or Tysabri with a superior safety profile. The TERACLES trial will evaluate the effect of combination therapy with interferon plus Teriflunimide.
To be eligible for this trial patients must be between the ages of 18 and 55 and must have had at least one relapse in the year prior to study entry while on interferon. They are then randomized to receive either placebo plus interferon or teriflunimide plus interferon.
Please use the NC ID number provided for each study and visit the clinicaltrials.gov website for more specific information on each study being conducted. If you would like more information on participating in clinical trials being conducted at Advance Neurology and Pain please contact Ashley Hodges at 336-940-2781 EXT 3462 or by email at ashley.hodges@cornerstonehealthcare.com.